利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.032 秒)

    Leukotriene antagonists
    3.
    发明授权
    Leukotriene antagonists 失效

    公开(公告)号：US4871771A

    公开(公告)日：1989-10-03

    申请号：US152191

    申请日：1988-02-04

    申请人： John G. Gleason ,  Sylvia T. Hoffstein ,  Charles M. Kinzig ,  Seymour Mong ,  Henry M. Sarau

    发明人： John G. Gleason ,  Sylvia T. Hoffstein ,  Charles M. Kinzig ,  Seymour Mong ,  Henry M. Sarau

    IPC分类号： A61K31/19 ,  A61P9/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/04 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07C323/56

    CPC分类号： A61K31/19

    摘要： A method for inhibiting the effects of LTB.sub.4 comprises administration of an effective amount of a compound represented by the following structural formula (I) ##STR1## wherein m is 1 or 2; n is 1, 2 or 3; p is 0, 1, or 2; R' is hydrogen or methyl; R is phenyl substituted with A, R.sub.1 and R.sub.2 wherein R.sub.1 and R.sub.2 are independently selected from either (1) (S).sub.a --(CH.sub.2).sub.b --(T).sub.c --B wherein a is 0 or 1; b is 5 to 12; c is 0 or 1; S and T are independently sulfur, oxygen, or CH.sub.2 with the proviso that S or T are not sulfur when p is 1 or 2; and B is C.sub.1-4 alkyl, ethynyl, trifluoromethyl, or phenyl optionally monosubstituted with Br, Cl, CF.sub.3, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, methylthio, or trifluoromethylthio; or (2) hydrogen bromo, chloro, methyl, trifluoromethyl, methoxy or nitro; and A is selected from (2) as defined above or a pharmaceutically acceptable salt thereof. Such methods are useful in the treatment of diseases in which LTB.sub.4 is a factor.

    HMTF81 human 7-transmembrane receptor
    5.
    发明授权
    HMTF81 human 7-transmembrane receptor 失效
    HMTF81人7-跨膜受体

    公开(公告)号：US06506878B1

    公开(公告)日：2003-01-14

    申请号：US09586924

    申请日：2000-06-05

    申请人： Catherine E. Ellis ,  Wendy Halsey ,  Ganesh M. Sathe ,  Robert S. Ames ,  James J. Foley ,  Henry M. Sarau ,  Jon Chambers

    发明人： Catherine E. Ellis ,  Wendy Halsey ,  Ganesh M. Sathe ,  Robert S. Ames ,  James J. Foley ,  Henry M. Sarau ,  Jon Chambers

    IPC分类号： C07K14705

    CPC分类号： C07K14/705 ,  A61K38/00 ,  A61K48/00

    摘要： HMTMF81 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HMTMF81 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

    摘要翻译： 公开了HMTMF81多肽和多核苷酸以及通过重组技术产生此类多肽的方法。 还公开了在设计用于治疗感染例如细菌，真菌，原生动物和病毒感染，特别是由HIV-1或HIV-2引起的感染的方案中使用HMTMF81多肽和多核苷酸的方法; 疼痛; 癌症; 厌食症 贪食 哮喘; 帕金森病 急性心力衰竭 低血压 高血压; 尿潴留 骨质疏松症 心绞痛; 心肌梗死; 溃疡 哮喘; 过敏 良性前列腺肥大; 以及精神病和神经障碍，包括焦虑，精神分裂症，躁狂抑郁症，del妄，痴呆，严重的精神发育迟滞和运动障碍，如亨廷顿病或Gilles dela Tourett综合征以及这些病症的诊断测定。

    Methods of screening for agonists and antagonists of the interaction between the human KIAA0001 receptor and ligands thereof
    7.
    发明授权
    Methods of screening for agonists and antagonists of the interaction between the human KIAA0001 receptor and ligands thereof 失效
    筛选人KIAA0001受体及其配体之间相互作用的激动剂和拮抗剂的方法

    公开(公告)号：US06238873B1

    公开(公告)日：2001-05-29

    申请号：US09303524

    申请日：1999-04-30

    申请人： Robert S. Ames ,  Anne Romanic Arnold ,  Jonathan K. Chambers ,  James Joseph Foley ,  Henry M. Sarau ,  Brian R. Stewart

    发明人： Robert S. Ames ,  Anne Romanic Arnold ,  Jonathan K. Chambers ,  James Joseph Foley ,  Henry M. Sarau ,  Brian R. Stewart

    IPC分类号： G01N3353

    CPC分类号： C07K14/705 ,  C07K2319/00 ,  G01N2333/726 ,  G01N2500/20

    摘要： Disclosed are methods for discovering agonists and antagonists of the interaction between UDP-glucose, UDP-galactose, UDP-glucuronic acid, UDP-N-acetyl glucosamine, as well as related UDP sugars, and their cellular receptor, human KIAA0001, which may have utility in the treatment of several human diseases and disorders, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; restenosis; atherosclerosis; diseases characterized by excessive smooth muscle cell proliferation; aneurysms; wound healing; diseases characterized by loss of smooth muscle cells or reduced smooth muscle cell proliferation; stroke; ischemia; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; degenerative diseases, such as neurodegenerative diseases and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others.

    摘要翻译： 公开了用于发现UDP-葡萄糖，UDP-半乳糖，UDP-葡糖醛酸，UDP-N-乙酰葡糖胺以及相关的UDP糖和它们的细胞受体之间的相互作用的激动剂和拮抗剂的方法，人类KIAA0001可能具有 包括但不限于：细菌，真菌，原生动物和病毒感染等感染，尤其是HIV-1或HIV-2引起的感染; 疼痛; 癌症; 糖尿病，肥胖; 厌食症 贪食 哮喘; 帕金森病 急性心力衰竭 低血压 高血压; 尿潴留 骨质疏松症 心绞痛; 心肌梗死; 再狭窄; 动脉粥样硬化 以过度平滑肌细胞增殖为特征的疾病; 动脉瘤 伤口愈合; 特征在于平滑肌细胞丧失或平滑肌细胞增殖减少的疾病; 行程; 缺血; 溃疡 哮喘; 过敏 良性前列腺肥大; 偏头痛 呕吐 精神病和神经障碍，包括焦虑，精神分裂症，躁狂抑郁症，抑郁症，del妄，痴呆和严重智力迟钝; 退行性疾病，如神经退行性疾病和运动障碍，如亨廷顿病或吉尔斯·德拉·图雷特综合征等。

    cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor
    9.
    发明授权
    cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor 失效
    编码新型人7-跨膜受体的cDNA克隆HMTMF81

    公开(公告)号：US06200775B1

    公开(公告)日：2001-03-13

    申请号：US09044404

    申请日：1998-03-19

    申请人： Catherine E. Ellis ,  Wendy Halsey ,  Ganesh M. Sathe ,  Robert S. Ames ,  James J. Foley ,  Henry M. Sarau ,  Jon Chambers

    发明人： Catherine E. Ellis ,  Wendy Halsey ,  Ganesh M. Sathe ,  Robert S. Ames ,  James J. Foley ,  Henry M. Sarau ,  Jon Chambers

    IPC分类号： C12N1512

    CPC分类号： C07K14/705 ,  A61K38/00 ,  A61K48/00

    摘要： HMTMF81 polypeptides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HMTMF81 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris, myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

    摘要翻译： 公开了HMTMF81多肽和通过重组技术产生此类多肽的方法。 还公开了在设计用于治疗感染例如细菌，真菌，原生动物和病毒感染，特别是由HIV-1或HIV-2引起的感染的方案中使用HMTMF81多肽和多核苷酸的方法; 厌食症 贪食 哮喘; 帕金森病 急性心力衰竭 低血压 高血压; 尿潴留 骨质疏松症 心绞痛，心肌梗死; 溃疡 哮喘; 过敏 良性前列腺肥大; 以及精神病和神经障碍，包括焦虑，精神分裂症，躁狂抑郁症，del妄，痴呆，严重的精神发育迟滞和运动障碍，如亨廷顿病或Gilles dela Tourett综合征以及这些病症的诊断测定。

    Methods of screening for agonists and antagonists for human CCR7 receptor and CK.beta.-9 ligand and interaction thereof
    10.
    发明授权
    Methods of screening for agonists and antagonists for human CCR7 receptor and CK.beta.-9 ligand and interaction thereof 失效
    筛选人CCR7受体和CKβ-9配体的激动剂和拮抗剂的方法及其相互作用

    公开(公告)号：US6153441A

    公开(公告)日：2000-11-28

    申请号：US251545

    申请日：1999-02-17

    申请人： Edward R. Appelbaum ,  Henry M. Sarau ,  John R. White

    发明人： Edward R. Appelbaum ,  Henry M. Sarau ,  John R. White

    IPC分类号： G01N33/68 ,  G01N33/566 ,  C12P21/02 ,  C12P21/06 ,  G01N33/53 ,  G01N33/567

    CPC分类号： G01N33/6863 ,  G01N2500/10

    摘要： Disclosed are methods for discovering agonists and antagonists of the interaction between a secreted human protein, chemokine CK.beta.-9, and its cellular receptor, human CCR7, which may have utility in the treatment of several human diseases, including, but not limited to: allergic disorders, autoimmune diseases, ischemia/reperfusion injury, development of atherosclerotic plaques, cancer (including mobilization of hematopoietic stem cells for use in chemotherapy or mycloprotection during chemotherapy), chronic inflammatory disorders, chronic rejection of transplanted organs or tissue grafts, chronic myelogenous leukemia, and infection by HIV and other pathogens.

    摘要翻译： 公开了用于发现激动剂和拮抗剂在分泌的人蛋白质趋化因子CKβ-9及其细胞受体人类CCR7之间的相互作用的方法，其可用于治疗几种人类疾病，包括但不限于： 过敏性疾病，自身免疫疾病，缺血/再灌注损伤，动脉粥样硬化斑块发展，癌症（包括动员化学干细胞用于化学疗法或化疗期间的微环境保护），慢性炎性疾病，移植器官或组织移植物的慢性排斥，慢性髓细胞白血病 ，以及艾滋病毒和其他病原体的感染。